Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Cardiotoxicity × Trastuzumab × Clear all

Phase

Status

Completed 3 Unknown 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 66 Stomach Neoplasms 10 Neoplasms 7 Neoplasm Metastasis 7 Esophageal Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Brain Neoplasms 4 Breast Neoplasms, Male 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Ovarian Neoplasms 2 Inflammatory Breast Neoplasms 2 HER2-positive Breast Cancer 2 Urologic Neoplasms 1 Solid Tumor 1 Salivary Gland Neoplasms 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Mycosis Fungoides 1 Meningeal Neoplasms 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, B-Cell, Marginal Zone 1 Locally Advanced Breast Cancer 1 Leukemia 1 Hodgkin Disease 1 Head and Neck Neoplasms 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER-2 Positive Breast Cancer 1

Interventions

Doxorubicin 3 Docetaxel 2 Cyclophosphamide 2 Trastuzumab 1 Neoadjuvant Therapy 1 Methotrexate 1 Leucovorin 1 High-Intensity Interval Training 1 Hematologic Tests 1 Filgrastim 1 Exercise 1 Epirubicin 1 Echocardiography 1 Dexrazoxane 1 Cisplatin 1 Chemotherapy, Adjuvant 1 Atorvastatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00377780 2015-09-23

MYOHERTAX

Catharina Ziekenhuis Eindhoven

Phase 2 Terminated

Breast Neoplasms, Neoplasm Metastasis, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡